Cargando…
A STING-Activating Nanovaccine for Cancer Immunotherapy
Generation of tumor-specific T cells is critically important for cancer immunotherapy(1,2). A major challenge in achieving a robust T cell response is the spatio-temporal orchestration of antigen cross-presentation in antigen presenting cells (APCs) with innate stimulation. Here we report a minimali...
Autores principales: | Luo, Min, Wang, Hua, Wang, Zhaohui, Cai, Haocheng, Lu, Zhigang, Li, Yang, Du, Mingjian, Huang, Gang, Wang, Chensu, Chen, Xiang, Porembka, Matthew R., Lea, Jayanthi, Frankel, Arthur E., Fu, Yang-Xin, Chen, Zhijian J., Gao, Jinming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500418/ https://www.ncbi.nlm.nih.gov/pubmed/28436963 http://dx.doi.org/10.1038/nnano.2017.52 |
Ejemplares similares
-
Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
por: Jiang, Xiaoyi, et al.
Publicado: (2022) -
Correction: Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
Publicado: (2022) -
STING agonist-boosted mRNA immunization via intelligent design of nanovaccines for enhancing cancer immunotherapy
por: Zhou, Lei, et al.
Publicado: (2023) -
Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy
por: Su, Ting, et al.
Publicado: (2022) -
In Situ Cocktail Nanovaccine for Cancer Immunotherapy
por: Liu, Mohan, et al.
Publicado: (2023)